The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension

  • Lee, Young Ho (Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Song, Gwan Gyu (Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine)
  • Received : 2012.11.29
  • Accepted : 2013.01.17
  • Published : 2013.11.01
⟨ Previous Next ⟩

Abstract

Background/Aims: We assessed the efficacy and safety of bosentan in patients with pulmonary arterial hypertension (PAH). Methods: We surveyed randomized controlled trials (RCTs) of the efficacy and safety of bosentan in patients with PAH using MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and manual searches. Meta-analysis of RCTs was performed to determine treatment efficacy and safety outcomes. Results are presented as odds ratios (ORs) or weighted mean differences (WMDs). Results: Meta-analysis of seven RCTs including a total of 410 patients and 296 controls revealed that the 6-minute work distance was significantly higher in the bosentan group than in the placebo group (WMD, 46.19; 95% confidence interval [CI], 21.20 to 71.19; $p=2.9{\times}10^{-5}$). Compared with the placebo, bosentan significantly reduced the mean pulmonary arterial pressure in patients with PAH (WMD, -6.026; 95% CI, -8.785 to -3.268, $p=1.8{\times}10^{-6}$). The bosentan therapy group worsened less clinically than the placebo group (OR, 0.252; 95% CI, 0.140 to 0.454; $p=4.6{\times}10^{-7}$). The incidence of serious adverse events did not differ between the bosentan and placebo groups (OR, 0.948; 95% CI, 0.556 to 1.614; p = 0.843). However, the results of the abnormal liver function test (LFT) were significantly higher in the bosentan group than in the placebo group (OR, 2.312; 95% CI, 1.020 to 5.241; p = 0.045). Conclusions: This meta-analysis shows that bosentan can treat PAH effectively. However, bosentan increased the incidence of abnormal LFT results compared with the placebo.

Keywords

References

  1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-117. https://doi.org/10.1056/NEJM199701093360207
  2. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61:227-237. https://doi.org/10.1016/j.cardiores.2003.11.026
  3. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165:398-405. https://doi.org/10.1164/ajrccm.165.3.2104059
  4. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-1123. https://doi.org/10.1016/S0140-6736(01)06250-X
  5. Valerio G, Bracciale P, Grazia D'Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009;3:15-21. https://doi.org/10.1177/1753465808103499
  6. Jais X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNop-Erable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52:2127-2134. https://doi.org/10.1016/j.jacc.2008.08.059
  7. Galie N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-2100. https://doi.org/10.1016/S0140-6736(08)60919-8
  8. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. https://doi.org/10.1056/NEJMoa012212
  9. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-359. https://doi.org/10.1183/09031936.04.00028404
  10. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54. https://doi.org/10.1161/CIRCULATIONAHA.106.630715
  11. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997;315:1533-1537. https://doi.org/10.1136/bmj.315.7121.1533
  12. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2006;27:157-161. https://doi.org/10.1007/s00296-006-0175-7
  13. Nath SK, Harley JB, Lee YH. Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum Genet 2005;118:225-234. https://doi.org/10.1007/s00439-005-0044-6
  14. Lee YH, Song GG. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med 2011;26:340-347. https://doi.org/10.3904/kjim.2011.26.3.340
  15. He B, Zhang F, Li X, et al. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 2010;74:1458-1464. https://doi.org/10.1253/circj.CJ-09-0971
  16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12. https://doi.org/10.1016/0197-2456(95)00134-4
  17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634. https://doi.org/10.1136/bmj.315.7109.629
  18. Davey Smith G, Egger M. Meta-analyses of randomised controlled trials. Lancet 1997;350:1182.
  19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558. https://doi.org/10.1002/sim.1186
  20. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-2056. https://doi.org/10.1016/j.jacc.2006.01.057
  21. Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380-1386. https://doi.org/10.1016/S0735-1097(03)00121-9
  22. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-628. https://doi.org/10.1183/09031936.00011308
  23. Provencher S, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opin Pharmacother 2005;6:1337-1348. https://doi.org/10.1517/14656566.6.8.1337
  24. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111. https://doi.org/10.1161/CIRCULATIONAHA.104.488486

Cited by

  1. Drug-induced liver injury: what was new in 2013? vol.10, pp.7, 2014, https://doi.org/10.1517/17425255.2014.909408
  2. Endothelin Blockade in Diabetic Kidney Disease vol.4, pp.6, 2013, https://doi.org/10.3390/jcm4061171
  3. Matrix Metalloproteinase 1 Causes Vasoconstriction and Enhances Vessel Reactivity to Angiotensin II via Protease-Activated Receptor 1 vol.23, pp.4, 2016, https://doi.org/10.1177/1933719115607998
  4. Diagnosis of Pulmonary Arterial Hypertension in Children by Using Cardiac Computed Tomography vol.20, pp.6, 2013, https://doi.org/10.3348/kjr.2018.0673